癌症多基因风险评分与放射治疗毒性发生风险无关联
研究纳入9,717例乳腺癌、前列腺癌或肺癌患者,前瞻性评估放疗毒性,检验癌症易感性多基因风险评分(PRS)是否影响放疗毒性风险。结果显示PRS升高未增加晚期或急性毒性风险;个别SNP与乳腺疼痛或水肿相关,需独立队列验证。
要点
- 乳腺癌、前列腺癌、肺癌患者PRS升高未增加晚期放疗毒性风险。
- 急性毒性结果与晚期毒性相似,PRS未显示增加风险。
- rs138944387与乳腺疼痛相关,rs17513613与乳腺水肿相关。
核心结论
- 对乳腺癌、前列腺癌或肺癌多基因易感性增高的患者可安全接受放疗,未预期有超额毒性风险。
- 个别SNP增加特定毒性终点的可能性,需在独立队列中验证并进行功能研究以阐明生物学机制。
研究设计与样本
- 分析纳入来自放射基因组学与REQUITE联盟队列的9,717例乳腺癌(n=3,078)、前列腺癌(n=5,748)或肺癌(n=891)患者。
- 患者接受潜在的根治性放疗,并前瞻性评估毒性。
- 生殖系基因分型采用全基因组单核苷酸多态性(SNP)芯片,未分型SNP进行填充。
- 每种癌症的PRS通过累加文献鉴定的癌症易感性风险等位基因生成:乳腺癌352个、前列腺癌136个、肺癌24个。
- 加权PRS使用癌症易感性的对数比值比(OR)生成。
主要发现
- PRS升高未增加乳腺癌患者晚期毒性风险(OR,1.000;95%CI,0.997-1.002)。
- PRS升高未增加前列腺癌患者晚期毒性风险(OR,0.99;95%CI,0.98-1.00;加权PRS OR,0.93;95%CI,0.83-1.03)。
- PRS升高未增加肺癌患者晚期毒性风险(OR,0.93;95%CI,0.87-1.00;加权PRS OR,0.68;95%CI,0.45-1.03)。
- 急性毒性结果与晚期毒性相似。
- 二次分析发现rs138944387与乳腺疼痛相关(OR,3.05;95%CI,1.86-5.01;P=1.09×10⁻⁵),rs17513613与乳腺水肿相关(OR,0.94;95%CI,0.92-0.97;P=1.08×10⁻⁵)。
关键数值与推荐
- 主要分析检验晚期标准化总平均毒性(STAT)评分,二次分析考察急性STAT、个体终点和SNP,采用多变量回归。
- STAT评分在2年和5年(乳腺癌、前列腺癌)或6至12个月(肺癌)量化毒性。
临床怎么用
- 原文未据此给出推荐。
局限性
- 个别SNP增加特定毒性终点的可能性,需在独立队列中验证并进行功能研究以阐明生物学机制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Our aim was to test whether updated polygenic risk scores (PRS) for susceptibility to cancer affect risk of radiation therapy toxicity. METHODS AND MATERIALS: Analyses included 9,717 patients with breast (n=3,078), prostate (n=5,748) or lung (n=891) cancer from Radiogenomics and REQUITE Consortia cohorts. Patients underwent potentially curative radiation therapy and were assessed prospectively for toxicity. Germline genotyping involved genome-wide single nucleotide polymorphism (SNP) arrays with nontyped SNPs imputed. PRS for each cancer were generated by summing literature-identified cancer susceptibility risk alleles: 352 breast, 136 prostate, and 24 lung. Weighted PRS were generated using log odds ratio (ORs) for cancer susceptibility. Standardized total average toxicity (STAT) scores at 2 and 5 years (breast, prostate) or 6 to 12 months (lung) quantified toxicity. Primary analysis tested late STAT, secondary analyses investigated acute STAT, and individual endpoints and SNPs using multivariable regression. RESULTS: Increasing PRS did not increase risk of late toxicity in patients with breast (OR, 1.000; 95% confidence interval [CI], 0.997-1.002), prostate (OR, 0.99; 95% CI, 0.98-1.00; weighted PRS OR, 0.93; 95% CI, 0.83-1.03), or lung (OR, 0.93; 95% CI, 0.87-1.00; weighted PRS OR, 0.68; 95% CI, 0.45-1.03) cancer. Similar results were seen for acute toxicity. Secondary analyses identified rs138944387 associated with breast pain (OR, 3.05; 95% CI, 1.86-5.01; P = 1.09 × 10-5) and rs17513613 with breast edema (OR, 0.94; 95% CI, 0.92-0.97; P = 1.08 × 10-5). CONCLUSIONS: Patients with increased polygenic predisposition to breast, prostate, or lung cancer can safely undergo radiation therapy with no anticipated excess toxicity risk. Some individual SNPs increase the likelihood of a specific toxicity endpoint, warranting validation in independent cohorts and functional studies to elucidate biologic mechanisms.
引用
- Barnett GC, Kerns SL, Dorling L, et al. No Association Between Polygenic Risk Scores for Cancer and Development of Radiation Therapy Toxicity. Int J Radiat Oncol Biol Phys. 2022. PMID: 35840111. doi:10.1016/j.ijrobp.2022.06.098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。